Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03093961




Registration number
NCT03093961
Ethics application status
Date submitted
15/03/2017
Date registered
28/03/2017
Date last updated
6/02/2024

Titles & IDs
Public title
REDUCE LAP-HFREF TRIAL
Scientific title
A Study to Evaluate the Corvia Medical, Inc. IASD® System II to REDUCE Elevated Left Atrial Pressure in Patients With Heart Failure With Reduced Ejection Fraction
Secondary ID [1] 0 0
1502
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Heart Failure 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Coronary heart disease
Cardiovascular 0 0 0 0
Other cardiovascular diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - IASD implant

Experimental: Intervention - IASD Implantation


Treatment: Devices: IASD implant
Single arm for implant
Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
The percent of subjects who experience major adverse cardiac and/or cerebrovascular events (MACCE)
Timepoint [1] 0 0
6 months
Primary outcome [2] 0 0
The percent of subjects who have successful device implantation
Timepoint [2] 0 0
Index Procedure
Primary outcome [3] 0 0
The percent of subjects left to right flow through the device
Timepoint [3] 0 0
6 months

Eligibility
Key inclusion criteria
1. Chronic symptomatic Heart Failure (HF) documented by the following:

1. New York Heart Association (NYHA) Class III/ambulatory class IV symptoms (Paroxysmal nocturnal dyspnea, Orthopnea, Dyspnea on mild or moderate exertion) at screening visit, and signs (e.g. any rales post cough, Chest x-ray demonstrating pulmonary congestion,) within past 12 months; AND
2. One hospital admission for which HF was a major component of the hospitalization within the 12 months prior to study entry (transient heart failure in the context of myocardial infarction does not qualify), or one emergency department visit with IV treatment for HF within the 12 months prior to study entry
2. Ongoing stable GDMT for HF (Class I, and IIa recommendations) according to the 2016 ACC/AHA Guidelines for the management of Heart Failure (with no significant changes [>100% increase or 50% decrease], excluding diuretic dose changes for a minimum of 3 months prior to screening), which is expected to be maintained without change for 6 months
3. Age = 18 years old
4. Reduced Left ventricular ejection fraction between 20% and 40% as documented by echocardiography, radio nuclide ventriculography, or MRI within the past 3 months
5. Elevated left atrial pressure with a gradient compared to right atrial pressure (RAP) documented by:

a. Resting end expiratory PCWP = 18 mmHg, and greater than RAP by = 5 mmHg
6. Subject has been informed of the nature of the study, agrees to its provisions and has provided written informed consent, as approved by the IRB
7. Subject is willing to comply with clinical investigation procedures and agrees to return for all required follow-up visits, tests, and exams
8. Trans-septal catheterization by femoral vein access is determined to be feasible
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Patients who are not receiving GDMT for specified reasons
2. NT-Pro BNP < 100 pg/mL (if in sinus rhythm), or <300 pg/mL (if in atrial fibrillation); or BNP < 70 pg/mL (if in sinus rhythm), or < 200 pg/mL (if in atrial fibrillation)
3. Myocardial infarction (MI) and/or percutaneous cardiac intervention within past 3 months; CABG in past 3 months, or current indication for coronary revascularization
4. Cardiac Resynchronization Therapy initiated within the past 3 months
5. Automated Implantable Cardioverter Defibrillator (AICD) placed within past 3 months
6. Severe heart failure defined by all of the following:

1. ACC/AHA/ESC Stage D heart failure, Non-ambulatory NYHA Class IV HF;
2. Cardiac Index < 2.0 L/min/m2
3. Requiring inotropic infusion (continuous or intermittent) within the past 3 months.
4. Listed on transplant waiting list
7. Ability to perform the 6 minute walk Test >600m
8. Known clinically significant un-revascularized coronary artery disease, defined as: epi-cardial coronary artery stenosis associated with angina or other evidence of coronary ischemia.
9. History of stroke, transient ischemic attack (TIA), deep vein thrombosis (DVT), or pulmonary emboli within the past 6 months or recurrent DVT/pulmonary emboli
10. Presence of significant valve disease defined by echocardiography as:

1. Mitral valve regurgitation defined as grade > 2+ MR
2. Tricuspid valve regurgitation defined as grade > 2+ TR;
3. Aortic valve disease defined as = 2+ AR or moderate AS
11. Subject is contraindicated to receive either dual antiplatelet therapy or warfarin analogue; or has a documented coagulopathy
12. Atrial fibrillation with resting HR > 100 BPM
13. Arterial Oxygen saturation < 95% on room air
14. Significant hepatic impairment defined as 3X upper limit of normal of transaminases, total bilirubin, or alkaline phosphatase; Hepatic cirrhosis; Hypoalbuminemia
15. Resting RAP > 14 mmHg
16. Right ventricular dysfunction, defined as

1. More than mild RV dysfunction as determined by TTE: OR
2. TAPSE < 1.4 cm: OR
3. RV volume = LV volume on echo estimate; OR
4. Evidence of RV dysfunction defined by echo as an RV fractional area change < 35%
17. Evidence of pulmonary hypertension with PVR =4 Woods Units
18. Chronic pulmonary disease requiring continuous home oxygen, OR significant chronic pulmonary disease defined as FEV1 <1L.
19. Currently participating in an investigational drug or device study that may interfere with the conduct and outcome of this study.
20. Life expectancy less than 12 months for non-cardiovascular reasons
21. Echocardiographic evidence of intra-cardiac mass, thrombus or vegetation
22. Known or suspected allergy to nickel
23. Women of child bearing potential
24. Currently requiring dialysis; or e-GFR <25ml/min
25. Systolic blood pressure >170 mmHg despite appropriate medical management
26. Subjects with existing or surgically closed (with a patch) Atrial Septal Defects. Subjects with a Patent Foramen Ovale (PFO), who have elevated filling pressure despite the PFO are allowed
27. Subjects on immunosuppression or systemic steroid treatment
28. In the opinion of the investigator, the subject is not an appropriate candidate for the study

Study design
Purpose of the study
Treatment
Allocation to intervention
NA
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
NA
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
10/03/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/12/2027
Actual
Sample size
Target
10
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
John Hunter Hospital - New Lambton Heights
Recruitment hospital [2] 0 0
St. Vincent Hospital - Sydney
Recruitment postcode(s) [1] 0 0
2305 - New Lambton Heights
Recruitment postcode(s) [2] 0 0
- Sydney
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
New York
Country [2] 0 0
Czechia
State/province [2] 0 0
Prague

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Corvia Medical
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Jan Komtebedde, DVM
Address 0 0
Corvia Medical
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT03093961